CDK9 and breast carcinoma: Compared with SNS-032, although they have similar kinase-binding profiles, THAL-SNS-032 selectively induces degradation of CDK9, with only CDK9 exhibiting more than two-log-fold significant downregulation.107 THAL-SNS-032 displayed profound inhibitory activity in MCF7, T47D, and BT474 breast cancer cell lines.